Samsara BioCapital, a leading biotech investor active across private and public markets, joins global investor syndicate Funds will be used to advance AP306, a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia in patients on dialysis Investment comes ahead of Phase 2b topline data, expected in H1 2027 Redwood City, California […]